
## Zin W Myint

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4061482/publications.pdf Version: 2024-02-01



ZIN W MVINT

#	Article	IF	CITATIONS
1	Copper deficiency anemia: review article. Annals of Hematology, 2018, 97, 1527-1534.	1.8	176
2	Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. Journal of Hematology and Oncology, 2017, 10, 86.	17.0	64
3	Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer. American Journal of Health-System Pharmacy, 2020, 77, 346-351.	1.0	40
4	Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies. Cancers, 2021, 13, 5417.	3.7	34
5	Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors. JAMA Network Open, 2020, 3, e2025826.	5.9	24
6	Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Review and a Single Center Experience. Lung, 2018, 196, 577-581.	3.3	18
7	Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters. Cancers, 2021, 13, 2157.	3.7	12
8	Radiopharmaceutical Validation for Clinical Use. Frontiers in Oncology, 2021, 11, 630827.	2.8	10
9	Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: An analysis from Kentucky Cancer Registry. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 17-22.	0.9	9
10	Disparities in prostate cancer survival in Appalachian Kentucky: a population-based study. Rural and Remote Health, 2019, 19, 4989.	0.5	6
11	Prostate Adenocarcinoma with Brain Metastasis: A Surveillance, Epidemiology, and End Results Database Analysis 2010-2015. Medical Science Monitor, 2021, 27, e930064.	1.1	4
12	Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2337-2347.	2.5	4
13	Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006–2013. Frontiers in Oncology, 2020, 10, 1125.	2.8	3
14	A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss. Frontiers in Oncology, 2021, 11, 731002.	2.8	3
15	Socioeconomic Disparities Affect Survival of Classical Hodgkin Lymphoma in a Statewide Cancer Registry Analysis. Blood, 2018, 132, 4836-4836.	1.4	0
16	CGE19-065: Number of Somatic Mutations Is an Independent Predictor of Overall Survival in Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, CGE19-065.	4.9	0
17	A single arm phase II study of bone-targeted Sn-117Âm-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases. BMC Cancer, 2022, 22, 415.	2.6	0